sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_10808> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_10808> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00927> ;
    a rdf:Statement ;
    rdfs:label "famotidine is indicated in most adult patients heal within 4 weeks there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks short term treatment of active duodenal ulcer controlled studies in adults have not extended beyond one year maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer most adult patients heal within 6 weeks studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks short term treatment of active benign gastric ulcer famotidine is indicated for short term treatment of patients with symptoms of gerd see famotidine is also indicated for the short term treatment of esophagitis due to gerd including erosive or ulcerative disease diagnosed by endoscopy see short term treatment of gastroesophageal reflux disease gerd clinical pharmacology in adults clinical studies clinical pharmacology in adults clinical studies treatment of pathological hypersecretory conditions e g zollinger ellison syndrome multiple endocrine adenomas see clinical pharmacology in adults clinical studies" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00927> bl:category bl:Drug .
}